Fibrotic and Sclerotic Manifestations of Chronic Graft-versus-Host Disease

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 1 SUPPL., 2012, Pages

  Kitko, Carrie L ^a   White, Eric S ^a   Baird, Kristin ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETABOLITE; AZITHROMYCIN; CALCINEURIN INHIBITOR; DECORIN; HALOFUGINONE; HYDROXYCHLOROQUINE; IMATINIB; MONTELUKAST; NILOTINIB; PIRFENIDONE; PREDNISONE; TRANSFORMING GROWTH FACTOR BETA;

AIRWAY OBSTRUCTION; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BRONCHIOLITIS OBLITERANS; BRONCHIOLITIS OBLITERANS SYNDROME; CHRONIC GRAFT VERSUS HOST DISEASE; DRUG MEGADOSE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INFECTION COMPLICATION; LUNG BIOPSY; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG LAVAGE; LUNG TRANSPLANTATION; MORTALITY; MYOFIBROBLAST; NONHUMAN; OVERALL SURVIVAL; PHENOTYPE; THORAX RADIOGRAPHY; UNSPECIFIED SIDE EFFECT;

BRONCHIOLITIS OBLITERANS; CHRONIC DISEASE; CYTOKINES; FEMALE; FIBROSIS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; PULMONARY FIBROSIS; SCLERODERMA, SYSTEMIC; SKIN DISEASES; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 84855394414     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.10.021     Document Type: Article

References (47)

1. Penas P.F., Jones-Caballero M., Aragues M., Fernandez-Herrera J., Fraga J., Garcia-Diez A. Sclerodermatous graft-vs-host disease: clinical and pathological study of 17 patients. Arch Dermatol 2002, 138:924-934.
2. Chien J.W., Duncan S., Williams K.M., Pavletic S.Z. Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2010, 16:S106-S114.
3. Distler J.H., Distler O. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies. Ann Rheum Dis 2010, 69(suppl 1):i48-i51.
4. Tarrats N., Moles A., Morales A., Garcia-Ruiz C., Fernandez-Checa J.C., Mari M. Critical role of tumor necrosis factor receptor 1, but not 2, in hepatic stellate cell proliferation, extracellular matrix remodeling, and liver fibrogenesis. Hepatology 2011, 54:319-327.
5. Mathai S.K., Gulati M., Peng X., et al. Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. Lab Invest 2010, 90:812-823.
6. Mattyasovszky S.G., Hofmann A., Brochhausen C., et al. The effect of the pro-inflammatory cytokine tumor necrosis factor-alpha on human joint capsule myofibroblasts. Arthritis Res Ther 2010, 12:R4.
7. Antoniou K.M., Mamoulaki M., Malagari K., et al. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin Exp Rheumatol 2007, 25:23-28.
8. Vassallo R., Matteson E., Thomas C.F. Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition. Chest 2002, 122:1093-1096.
9. Kaya Z., Weiner D.J., Yilmaz D., Rowan J., Goyal R.K. Lung function, pulmonary complications, and mortality after allogeneic blood and marrow transplantation in children. Biol Blood Marrow Transplant 2009, 15:817-826.
10. Au B.K., Au M.A., Chien J.W. Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011, 17:1072-1078.
11. Dudek A., Mahaseth H., DeFor T., Weisdorf D. Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant 2003, 9:657-666.
12. Shulman H.M., Kleiner D., Lee S.J., et al. Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant 2006, 12:31-47.
13. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
14. Williams K.M., Chien J.W., Gladwin M.T., Pavletic S.Z. Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA 2009, 302:306-314.
15. Chien J.W., Martin P.J., Gooley T.A., et al. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2003, 168:208-214.
16. Hildebrandt G.C., Fazekas T., Lawitschka A., et al. Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD. Bone Marrow Transplant 2011, 46:1283-1295.
17. Norman B.C., Jacobsohn D.A., Williams K.M., et al. Fluticasone, azithromycin and montelukast therapy in reducing corticosteroid exposure in bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: a case series of eight patients. Bone Marrow Transplant 2011, 46:1369-1373.
18. Yanik, et al. Biol Blood Marrow Transplant, in press.
19. White E.S., Baralle F.E., Muro A.F. New insights into form and function of fibronectin splice variants. J Pathol 2008, 216:1-14.
20. Moore B.B., Hogaboam C.M. Murine models of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2008, 294:L152-L160.
21. Daniels C.E., Lasky J.A., Limper A.H., Mieras K., Gabor E., Schroeder D.R. Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results. Am J Respir Crit Care Med 2010, 181:604-610.
22. Price A.P., England K.A., Matson A.M., Blazar B.R., Panoskaltsis-Mortari A. Development of a decellularized lung bioreactor system for bioengineering the lung: the matrix reloaded. Tissue Eng Part A 2010, 16:2581-2591.
23. Macchiarini P., Jungebluth P., Go T., et al. Clinical transplantation of a tissue-engineered airway. Lancet 2008, 372:2023-2030.
24. Petersen T.H., Calle E.A., Zhao L., et al. Tissue-engineered lungs for invivo implantation. Science 2010, 329:538-541.
25. Ott H.C., Clippinger B., Conrad C., et al. Regeneration and orthotopic transplantation of a bioartificial lung. Nat Med 2010, 16:927-933.
26. Skert C., Patriarca F., Sperotto A., et al. Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome. Haematologica 2006, 91:258-261.
27. Barausse G., Caramaschi P., Scambi C., et al. Clinical, serologic and instrumental data of ten patients affected by sclerodermatous chronic graft versus host disease: similarities and differences in respect to systemic sclerosis. Int J Immunopathol Pharmacol 2010, 23:373-377.
28. Martin P.J., Weisdorf D., Przepiorka D., et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant 2006, 12:491-505.
29. Svegliati S., Olivieri A., Campelli N., et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 2007, 110:237-241.
30. Okamoto M., Okano A., Akamatsu S., et al. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia 2006, 20:172-173.
31. Distler J.H., Jungel A., Huber L.C., et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007, 56:311-322.
32. Abdollahi A., Li M., Ping G., et al. Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med 2005, 201:925-935.
33. Cohen M.H., Dagher R., Griebel D.J., et al. U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid. Oncologist 2002, 7:393-400.
34. Cohen M.H., Johnson J.R., Pazdur R. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. Clin Cancer Res 2005, 11:12-19.
35. Cools J., DeAngelo D.J., Gotlib J., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003, 348:1201-1214.
36. Daniels C.E., Wilkes M.C., Edens M., et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004, 114:1308-1316.
37. Majhail N.S., Schiffer C.A., Weisdorf D.J. Improvement of pulmonary function with imatinib mesylate in bronchiolitis obliterans following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006, 12:789-791.
38. DeAngelo D.J., Hochberg E.P., Alyea E.P., et al. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clin Cancer Res 2004, 10:5065-5071.
39. Magro L., Mohty M., Catteau B., et al. Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood 2009, 114:719-722.
40. Olivieri A., Locatelli F., Zecca M., et al. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood 2009, 114:709-718.
41. Rockey D.C. Antifibrotic therapy in chronic liver disease. Clin Gastroenterol Hepatol 2005, 3:95-107.
42. Zion O., Genin O., Kawada N., et al. Inhibition of transforming growth factor beta signaling by halofuginone as a modality for pancreas fibrosis prevention. Pancreas 2009, 38:427-435.
43. Azuma A., Nukiwa T., Tsuboi E., et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005, 171:1040-1047.
44. Noble P.W., Albera C., Bradford W.Z., et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011, 377:1760-1769.
45. Rationale and design of the chronic GVHD cohort study: improving outcomes assessment in chronic GVHD. Biol Blood Marrow Transplant 2011, 17:1114-1120.
46. Pidala J., Kim J., Anasetti C., et al. NIH Consensus chronic graft vs. host disease global severity is associated with overall survival and non-relapse mortality. Haematologica 2011.
47. Pidala J., Kurland B., Chai X., et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood 2011, 117:4651-4657.